Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of [225Ac]-AZD2284 in mCRPC
NCT06879041Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- Apr 2029
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 1, open-label trial of AZD2284 in metastatic castration-resistant prostate cancer (mCRPC) (9 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events up to 5 years, Dose Limiting Toxicities up to 84 days and 4 more. Started Mar 2025; status: recruiting.
02
Drugs
AZD2284
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06879041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06879041.